Digestive Oncology Studies

A Phase 3, Multicenter, Open-Label, Randomized Study of Efficacy and Safety of MK-2870 versus a treatment of the doctor's choice in 3L+ advanced/metastatic gastroesophageal adenocarcinoma.

A phase 3, randomized, open-label, actively controlled trial of Sotorasib, Panitumumab and Folfiri versus researcher choice (Folfox or Folfiri) with or without Bevacizumab for the treatment of naive metastatic colorectal cancer patients with KRAS P.G12c mutation.

A phase 3, randomized, double-blind trial, where the muscle mass is measured from patients with colon cancer or lung cancer who, during treatment, a oral food supplement with high protein and energy content drink. The research will determine whether the new dietary supplement can limit muscle breakdown during treatment.

A phase 2, randomized trial to assess the safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid and Bevacizumab in previously treated patients with unresectable metastatic colorectal cancer to be determined.

A phase 3, open-label, randomized trial of preoperative and post-operative treatment with Dostarlimab alone versus standard treatment in patients with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer.

A multicenter, open-label, randomized, controlled phase II trial comparing the efficacy of RO7198457 versus watchful waiting in patients with resected colorectal cancer into stage II (high risk) and stage III who ctDNA positive are after resection.

A multicenter prospective study where people are looking for a personalized multimodal treatment of esophageal cancer based on the detection of minimal residual disease via circulating tumor DNA.

A global, randomized, controlled, open-label phase 1b/3 trial comparing treatment with RYZ101 with standard treatment in patients with inoperable progressive somatostatin receptor-positive evaluation (SSTR+), well-differentiated GEPNETs that progressed after previous 177 Lu-labeled somatostatin (177Lu-SSA) analog therapy.

Preoperative treatment with mFolfirinox (or Gem-Nab-P) +/- isotoxic high-dose stereotactic body radiation therapy (IHD-SBRT) for borderline resectable pancreatic adenocarcinoma: a randomized phase II trial.

Stereotactic radiation for the treatment of patients with a inoperable, non-metastatic pancreatic tumour: one randomized phase II trial.

Research project around the search for biomarkers for treatment with immunotherapy in Hepatocellular Carcinoma (HCC).

A phase 3, randomized trial with trastuzumab-deruxtecan (T-dxd) and Rilvegostomig versus standard gemcitabine, cisplatin, and durvalumab for primary care locally advanced or metastatic HER2 expression of biliary tract cancer.

A phase 2, open-label, randomized trial of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in patients with previously untreated T4N0 or stage III MMRP/MSS colon cancer.

One open-label, randomized trial where one investigates the usefulness of the continuation of somatostatin analogs after progression in patients with neuroendocrine tumors (NET) of the stomach, intestine, or pancreas who not hormonally active is.